Effects of antiprogestins on the uterus

Women's Health

Volumn 4, Issue 3, 2008, Pages 269-280

  Ouzounian, Sophie ^a   Bouchard, Philippe ^a,b   Chabbert Buffet, Nathalie ^c  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL TENON   (France)

Author keywords

Antiprogestins; Bleeding; Contraception; Endometrium; Myoma; Progesterone receptor; Progestins; Uterus

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE; ANTIGESTAGEN; ASOPRISNIL; ESTRADIOL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; ONAPRISTONE; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR MODULATOR; STEROID; TESTOSTERONE DERIVATIVE; ULIPRISTAL; VA 2914;

BLEEDING; BLEEDING DISORDER; BREAKTHROUGH BLEEDING; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRACEPTION; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EMERGENCY CONTRACEPTION; ENDOMETRIOSIS; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUTEOLYSIS; MONOTHERAPY; NONHUMAN; PREGNANCY TERMINATION; PREOPERATIVE TREATMENT; PROGESTERONE BLOOD LEVEL; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; UTERUS BLEEDING; UTERUS FUNCTION; UTERUS MYOMA; VAGINA BLEEDING; WOMEN'S HEALTH;

ANIMALS; CONTRACEPTIVES, ORAL, SYNTHETIC; FEMALE; HORMONE ANTAGONISTS; HUMANS; LEIOMYOMA; METRORRHAGIA; MIFEPRISTONE; PROGESTINS; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS; UTERUS;

EID: 44649084524     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.3.269     Document Type: Review

References (113)

1. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz I: Selective progesterone receptor modulators and progesterone antagonists: mechanism of action and clinical applications. Hum. Reprod. Update 11, 293-307 (2005).
2. Mulac Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM: Subgroup of reproductive functions of progesterone mediated by progesterone rcceptor-B isoform. Sciences 289, 1751-1754 (2000).
3. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP: The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromocyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol. Cell. Biol. 18, 1369-1378 (1998).
4. Liu Z, Auboeuf D, Wong J et al.: Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. USA 99, 7940-7944 (2002).
5. Smith C, O'Malley BW. Coregulator functions: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004).
6. O'Malley BW: Coregulators: from whence came these 'master genes'. Mol. Endocrinol. 21, 1009-1013 (2007).
7. Han SJ, DeMayo FJ, Xu J, Tsai SY, Tsai MJ, O'Malley BW: Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. Mol. Endocrinol. 20, 45-55 (2006).
8. Han SJ, Jeong J, Demayo FJ et al.: Dynamic cell type specificity of SRC-1 coactivator in modulating uterine progesterone receptor function in mice. Mol. Cell. Biol. 25, 8150-8165 (2005).
9. Ye X, Han SJ, Tsai SY et al.: Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. Proc. Natl. Acad. Sci. USA 102, 9487-9492 (2005).
10. Madauss KP, Grygielko ET, Deng SJ et al.: A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol. Endocrinol. 21, 1066-1081 (2007).
11. Taylor AH, McParland PC, Taylor DJ, Bell SC: The progesterone receptor in human term amniochorion and placenta is isoform C. Endocrinology 147, 687-693 (2006).
12. Condon JC, Hardy DB, Kovaric K, Mendelson CR: Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-{κ} B may contribute to the onset of labor through inhibition of PR function. Mol. Endocrinol. 20, 764-775 (2006).
13. Hammes SR, Levin ER: Extranuclear steroid receptors: nature and actions. Endocr. Rev. 28(7), 726-741 (2007).
14. Karteris E, Zervou S, Pang Y et al.: Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol. Endocrinol. 20, 1519-1534 (2006).
15. Gregory CW, Wilson EM, Apparao KB et al.: Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J. Clin. Endocrinol. Metab. 87, 2960-2966 (2002).
16. Mote PA, Balleine RL, McGowan EM, Clarke CL: Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 84, 2963-2971 (1999).
17. Wang H, Critchley HO, Kelly RW, Shen D, Baird D: Progesterone receptor subtype B is differentially, regulated in human endometrial stroma. Mol. Hum. Reprod. 4, 407-412 (1998).
18. More PA, Balleine RL, McGowan EM, Clarke CL: Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum. Reprod. 15(Suppl. 3), 48-56 (2000).
19. Arnett Mansfield RL, deFazio A, Wain GV et al.: Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 61, 4576-4582 (2001).
20. Vienonen A, Miertinen S, Blauer M et al.: Expression of nuclear receptors and cofactors in human endometrium and myometrium. J. Soc. Gynecol. Investig. 11, 104-112 (2004).
21. Philibert D, Deraedt R, Teutsch G: RU 38486, a potent antiglucocorticoid in vivo. Presented at: The VII International Congress of Pharmacology. Tokyo, Japan (1981).
22. Gravanis A, Schaison G, George M et al.: Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J. Clin. Endocrinol. Metab. 60, 156-163 (1985).
23. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K: Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 65, 713-723 (2000).
24. Spitz I: Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 68, 981-93 (2003).
25. Attardi BJ, Burgenson J, Hild SA, Reel JR: In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 88, 277-288 (2004)
26. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP: CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol. Cell Endocrinol. 188, 111-123 (2002).
27. Schubert G, Elger W, Kaufmann G, Schneider B, Reddersen G, Chwalisz K: Discovery chemistry, and reproductive pharmacology of asoprisnil and related 11β-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin. Reprod. Med. 23, 58-73 (2005).
28. Banaszak S, Brudney A,Donnelly K, Chai D, Chwalisz K, Fazleabas AT: Modulation of the action of chorionic gonadotropin in the baboon (Papio anubis) uterus by a progesterone receptor antagonist (ZK 137.316). Biol Reprod. 63, 820-825 (2000).
29. Petersen A, Bentin-Ley U, Ravn V et al.: The antiprogesterone Org 31710 inhibits human blastocyst-endometrial interactions in vitro. Fertil, Steril. 83(Suppl. 1), 1255-1263 (2005).
30. Lalitkumar PGL, Lalitkumar S, Meng CX et al.: Mifepristonc, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum. Reprod. 22, 3031-3037 (2007).
31. Herrmann W, Wyss R, Riondel A et al.: The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C.R. Acad. Sci. III 294, 933-938 (1982).
32. Swahn ML, Bygdeman M, Cekan S, Xing S, Masironi B, Johannisson E: The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum. Reprod. 5, 402-408 (1990).
33. Gemzell Danielsson K, Swahn ML, Svalander P, Bygdeman M: Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum. Reprod. 8, 870-873 (1993).
34. Cameron ST, Critchley HO, Buckley CH, Kelly RW, Baird DT: Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertil. Steril. 67, 1046-1053 (1997).
35. World Health Organization: Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task force on postovulatory methods of fertility regulation. Lancet 353, 697-702 (1999).
36. Xiao BL, von Hertzen H, Zhao H, Piaggio G: A randomized double-blind comparison of two single doses of mifepristone for emergency contraception. Hum. Reprod. 17, 3084-3089(2002).
37. Ashok PW, Wagaarachchi PT, Flett GM, Templeton A: Mifepristone as a late post-coital contraceptive. Hum. Reprod. 16, 72-75 (2001).
38. von Hertzen H, Piaggio G, Ding J et al.: Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 360, 1803-1810 (2002).
39. Thorne S, Nelson-Piercy C, MacGregor A et al.: Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J. Fam. Plann. Reprod. Health Care 32, 75-81 (2006).
40. Ashok PW, Kidd A, Flett GMM, Fitzmaurice A, Graham W, Templeton A: A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. Hum. Reprod. 17, 92-98 (2002).
41. Psychoyos A, Nikas G, Saranits L, Gravanis A: Hormone anti-implatation agents: antiprogestins. Hum. Reprod. 10(Suppl. 1), 140-150 (1995).
42. Creinin MD, Schlaff W, Archer DF et al.: Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet. Gynecol. 108, 1089-1097 (2006).
43. Shoupe D, Mishell DR Jr, Lahreenmaki P et al.: Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase. Am. J. Obstet. Gynecol. 157, 1415-1420 (1987).
44. Spitz IM, Shoupe D, Sitruk-Ware R, Mishell DR Jr: Response to die antiprogestagen RU 486 (mifepristone) during early pregnancy and the menstrual cycle in women. J. Reprod. Fertil. Suppl. 37, 253-260 (1989).
45. Escudero EL, Boerrigter PJ, Bennink HJ et al.: Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinizatton in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. J. Clin. Endocrinol. Metab. 90, 2081-2088 (2005).
46. Verbost PM, Hanssen RG, Korver GH, Mulders TM: ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens. Semin. Reprod. Med. 23, 101-111 (2005).
47. Gemzell-Danielsson K, Van Heusden AM, Killick SR et al.: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum. Reprod. 17, 2588-2593 (2002).
48. Cheng L, Zhu H, Wang A. Ren F, Chen J, Glasier A: Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum. Reprod. 15, 1969-1972 (2000).
49. Critchley HOD, Kelly RW, Brenner RM, Baird DT: The endocrinology of menstruation - a role for the immune system. Clin. Endocrinol. (Oxf.) 55(6), 701-710 (2001).
50. The Eshre Capri Workshop Group: Endometrial bleeding. Hum. Reprod. 13, 421-431 (2007).
51. Archer DF: Endometrial bleeding during hormone therapy: the effect of progestogens. Maturitas 57, 71-76 (2007).
52. Glasier AF, Wang H, Davie JE, Kelly RW, Critchley HO: Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using Norplant: a pilot study. Fertil. Steril. 77, 366-372 (2002).
53. Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC: Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 68, 1115-1119 (2003).
54. Jain JK, Li A, Yang W, Minoo P, Felix JC: Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Tertil. Steril. 87, 8-23 (2007).
55. Jain JK, Li A, Yang W, Minoo P, Felix JC: Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate. Hum. Reprod. 21, 798-809 (2006).
56. Li A, Felix JC, Yang W, Xiong DW, Minoo P, Jain JK: Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. Contraception 76, 57-65 (2007).
57. Grow DR, Reece MT, Hsiu JG et al.: Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. Fertil. Steril. 69, 936-943 (1998).
58. Heikinheimo O, Hsiu JG, Gordon K et al.: Endometrial effects of RU486 in primates - antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J. Steroid Biochem. Mol. Biol. 59, 179-90 (1996).
59. Neulen J, Williams RF, Breckwoldt M, Chwalisz K, Baulieu EE, Hodgen GD: Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. Hum. Reprod. 11, 1533-1537 (1996).
60. Slayden OD, Zelinski-Wooten MB, Chwalisz K, Stouffer RL, Brenner RM: Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum. Reprod. 13, 269-277 (1998).
61. Hodgen GD, van Uem JF, Chillik CF et al.: Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum. Reprod. 9(Suppl. 1), 77-81 (1994).
62. Baird DT, Thong KJ, Hall C, Cameron ST: Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days. Hum. Reprod. 10, 2270-2276 (1995).
63. Couzinet B, Young J, Kujas M et al.: The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J. Clin. Endocrinol. Metab. 84, 4191-4196 (1999).
64. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L: Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. 18, 61-68 (2003).
65. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P: Low dose continuous administration of the progesterone receptor modulator VA 2914, effect on the hypothalamus-pituitary-ovarian axis and the endometrium. Data from a prospective placebo controlled trial. J. Clin. Endocrinol. Metab. 92(9), 3582-3589 (2007).
66. Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS: Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J. Clin. Endocrinol. Metab. 65, 1135-1140 (1987).
67. Spitz IM: Progesterone antagonists and progesterone receptor modulators. Expert Opin. Investig. Drugs 12, 1693-1707 (2003).
68. Gemzell Danielsson K, Swahn ML, Westlund P, Johannisson E, Seppala M, Bygdeman M: Effect of low daily doses of mifepristone on ovarian function and endometrial development. Hum. Reprod. 12, 124-131 (1997).
69. Cameron ST, Thong KJ, Baird DT: Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth. Clin. Endocrinol. (Oxf.) 43, 407-414 (1995).
70. Ledger WL, Sweeting VM, Hillier H, Baird DT: Inhibition of ovulation by low-dose mifepristone (RU 486). Hum. Reprod. 7, 945-950 (1992).
71. Brown A, Cheng L, Lin S, Baird DT: Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J. Clin. Endocrinol. Metab. 87, 63-70 (2002).
72. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L: The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum. Reprod. 20, 1090-1099 (2005).
73. Pei K, Xiao B, Jing X, Lu S, Wei L, Zhao H: Weekly contraception with mifepristone. Contraception 75, 40-44 (2007).
74. Heikinheimo O, Vani S, Carpen O et al.: Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum. Reprod. 22, 2515-2522 (2007).
75. Nayak NR, Slayden OD, Mah K, Chwalisz K, Brenner RM: Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception. Contraception 75, S104-S111 (2007).
76. Ravet S, Labied S, Blacher S et al.: Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time. Hum. Reprod. 22, 3084-3091 (2007).
77. Classen-Linke I, Krusche CA, Chwalisz K, Rath W, Beier HM: Progestins and progesterone receptor modulators change vegf release of endometrial cells in culture. In: Progesterone and Progesterone Receptor Modulators. Spitz IM (Ed.). Steroids 65(10-11), 763-771 (2000).
78. Narvekar N, Critchley HO, Cheng L, Baird DT: Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum. Reprod. 21, 2312-2318 (2006).
79. Mirkin S, Archer DF: Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone. Contraception 70, 327-333 (2004).
80. Classen-Linke I, Alfer J, Krusche CA, Chwalisz K, Rath W, Beier HM: Progestins, progesterone receptor modulators, and progesterone antagonists change VEGF release of endometrial cells in culture. Steroids 65, 763-771 (2000).
81. Steinauer J, Pritts EA, Jackson R, Jacoby AF: Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet. Gynecol. 103, 1331-1336 (2004).
82. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS: Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. 101, 243-250 (2003).
83. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA: A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil. Steril. 87, 1399-1412 (2007).
84. Xu Q, Takekida S, Ohara N et al.: Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and upregulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J. Clin. Endocrinol. Metab. 90, 953-961 (2005).
85. Chen W, Ohara N, Wang J et al.: A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J. Clin. Endocrinol. Metab. 91, 1296-1304 (2006).
86. Wang J, Ohara N, Wang Z et al.: A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFβ3 and their receptors in cultured uterine leiomyoma cells. Hum. Reprod. 21, 1869-1877 (2006).
87. Maruo T, Ohara N, Matsuo H et al.: Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 75, S99-S103 (2007).
88. Yin P, Lin Z, Cheng YH et al.: Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J. Clin. Endocrinol. Metab. 92, 4459-4466 (2007).
89. Xu Q, Ohara N, Chen W et al.: Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum. Reprod. 21, 2408-2416 (2006).
90. Horne FM, Blithe DL: Progesterone receptor modulators and the endometrium: changes and consequences. Hum. Reprod. Update 13, 567-580 (2007).
91. Spitz IM, Chwalisz K: Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 65, 807-815 (2000).
92. Chwalisz K, Stockemann K, Fritzemeier KH, Fuhrmann U: Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum. Reprod. Update 4, 570-583 (1998).
93. Chwalisz K, Brenner RM, Fuhrmann UU, Hess Stumpp H, Elger W: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 65, 741-751 (2000).
94. Brenner RM, Slayden OD, Rodgers WH et al.: Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum. Reprod. 18, 1185-1193 (2003).
95. Noyes RW, Hertig AT, Rock J: Dating the endometrial biopsy. Fertil. Steril. 1, 3-25 (1950).
96. Catalano RD, Critchley HO, Heikinheimo O et al.: Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol. Hum. Reprod. 13, 641-654 (2007).
97. Cheon YP, Li Q, Xu X. DeMayo FJ, Bagchi IC, Bagchi MK: A genomic approach to identify novel progesterone receptor regulated pathways in the uterus during implantation. Mol. Endocrinol. 16, 2853-2871 (2002).
98. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C: Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 61, 4311-4314 (2001).
99. Fleischer AC, Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald B: Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J. Ultrasound Med. 18, 503-512 (1999).
100. Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C, Ranstam J: Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res. 20, 4889-4891 (2000).
101. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L: Effect of long-terim treatment with low-dose mifepristone on the endometrium. Hum. Reprod. 18, 61-68 (2003).
102. Lakha F, Ho PC, Van der Spuy ZM et al.: A novel estrogen-free oral contraceptive pill fbr women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum. Reprod. 22, 2428-2436 (2007).
103. Cameron ST, Glasier AF, Narvekar N, Gebbie A, Critichley HO, Baird DT: Effects of onapristone on postmenopausal endometrium. Steroids 68, 1053-1059 (2003).
104. Steinhauer J, Pritts EA. Jackson R, Jacoby AF: Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet. Gynecol. 103, 1331-1336 (2004).
105. Mutter GL, Bergeron C, Deligdisch L et al.: The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod. Pathol. DOI:10.1038/modpathol, 2008.19. (2008) (Epub ahead of print).
106. Williams AR, Critchley HO, Osei J et al.: The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum. Reprod. 22, 1696-1704 (2007).
107. Klijn JG, Setyono Han B, Fockens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65, 825-830 (2000).
108. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467-170 (2006).
109. Croxatto HB, Salvatierra AM, Fuentealba B, Massai R: Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Hum. Reprod. 13, 3297-3302 (1998).
110. Murphy AA, Kettel LM, Morales AJ, Roberts V, Parmley T, Yen SS: Endometrial effects of long-term low-dose administration of RU486. Fertil. Steril. 63, 761-766 (1995).
111. Grunberg SM, Weiss MH, Russell CA et al.: Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 24, 727-733 (2006).
112. Martineau PA, Levental M: Large endometrial polyp in a patient on long-term mifepristone therapy. J. Ultrasound Med. 19, 487-489 (2000).
113. Newfield RS, Spitz IM, Isacson C, New MI: Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol. (Oxf.) 54, 399-404 (2001).